Gentherm Insider Sold Shares Worth $1,255,930, According to a Recent SEC Filing-March 2024-www.financetom.com

Gentherm Insider Sold Shares Worth $1,255,930, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Gentherm Insider Sold Shares Worth $1,255,930, According to a Recent SEC Filing

Nov 22, 2024 2:11 PM

04:40 PM EST, 11/22/2024 (MT Newswires) -- Phillip Eyler, Director, President & CEO, on November 21, 2024, sold 29,684 shares in Gentherm ( THRM ) for $1,255,930. Following the Form 4 filing with the SEC, Eyler has control over a total of 147,317 shares of the company, with 147,317 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/903129/000095017024130254/xslF345X05/ownership.xml

Previous page： Pembina Pipeline Advances Greenlight Power Project in Alberta With Kineticor Next page： AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Pembina Pipeline Advances Greenlight Power Project in Alberta With Kineticor

Oct 6, 2025

08:04 AM EDT, 10/06/2025 (MT Newswires) -- Pembina Pipeline ( PBA ) said Monday that it remains focused on advancing the Greenlight Electricity Centre in Alberta with project partner Kineticor, an OPTrust portfolio company. The announcement comes as RBC Capital Markets cited an unconfirmed report that Pembina is close to announcing a data center deal with Meta. The project includes...

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Oct 6, 2025

Oct 6 (Reuters) - Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca ( AZN ) a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a deal worth up to $555 million. Under the deal, AstraZeneca ( AZN ) will get exclusive rights to develop therapies that target immune system-related disorders....

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Oct 6, 2025

(Reuters) -Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca ( AZN ) a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a deal worth up to $555 million. Under the deal, AstraZeneca ( AZN ) will get exclusive rights to develop therapies that target immune system-related disorders. The Anglo-Swedish pharmaceutical...

Ares Management Snags $2.9 Billion Stake In US Renewable Energy Portfolio

Oct 6, 2025

On Monday, Ares Management Corporation ( ARES ) disclosed that a fund under its Ares Infrastructure Opportunities strategy acquired a 49% stake in a portfolio of assets owned by EDP Renováveis, S.A. (EDPR) for approximately $2.9 billion. The deal includes a diversified portfolio of 10 projects totaling 1,632 megawatts of capacity, comprising 1,030 MW of solar, 402 MW of wind,...